

CALMARE THERAPEUTICS Inc  
Form SC 13G/A  
February 14, 2018  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4 - Exit Filing)\*

Calmare Therapeutics Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

204512107

(CUSIP Number)

December 31, 2017

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP No. 204512107

Names of Reporting  
Persons. I.R.S.

1. Identification Nos. of  
above persons (entities  
only)  
Joseph M. Finley

- Check the Appropriate  
2. Box if a Member of a  
Group (See Instructions)  
(a)   
(b)

3. SEC Use Only

- Citizenship or Place of  
4. Organization  
USA

Number of Shares Beneficially Owned by Each Reporting Person  
Sole Voting Power  
1,509,753  
Shared Voting Power  
0  
Sole Dispositive Power  
1,509,753  
Shared Dispositive Power  
0

9. Aggregate Amount  
Beneficially Owned by  
Each Reporting Person  
1,509,753

- Check if the Aggregate  
Amount in Row (9)  
10. Excludes Certain Shares  
(See Instructions)

- Percent of Class  
11. Represented by Amount  
in Row (9)  
4.97%\*

- Type of Reporting Person  
12. (See Instructions)  
IN

\* The percentage of class is calculated based on 30,376,639 outstanding shares of common stock as of November 16, 2017, as reported in the Issuer's First Amendment to Definitive Proxy Statement on Schedule 14A.

**Item 1(a) Name of Issuer:**

Calmare Therapeutics Incorporated

**Item 1(b) Address of Issuer's Principal Executive Offices:**

1375 Kings Highway East, Suite 400, Fairfield, Connecticut 06824

**Item 2(a) Name of Person Filing:**

Joseph M. Finley

**Item 2(b) Address of Principal Business Office or, if none, Residence:**

1157 Summit Avenue, St. Paul, MN 55105

**Item 2(c) Citizenship:**

USA

**Item 2(d) Title of Class of Securities:**

Common Stock

**Item 2(e) CUSIP Number:**

204512107

**Item 3. If this statement is filed pursuant to § 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a(n):**

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

**Item 4. Ownership**

(a) Amount beneficially owned:

1,509,753 shares. The reporting person may be deemed the beneficial owner of 726,213 shares held through the reporting person's individual retirement account and 783,540 shares held by Birch Coulee Fund, LLC, of which the reporting person is President.

Percent of class:

(b)  
4.97%

(c) Number of shares as to which the person has:

sole power to vote or to direct the vote:

(i)  
1,509,753

shared power to vote or to direct the vote:

(ii)  
0

sole power to dispose or to direct the disposition of:

(iii)  
1,509,753

shared power to dispose or to direct the disposition of:

(iv)  
0

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. [X]

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company**

Not Applicable

**Item 8. Identification and Classification of Members of the Group** Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

*[Signature Page Follows]*



**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13 , 2018

/s/ Joseph M. Finley

Joseph M. Finley